Go to the list of all blogs
Serhii Bondarenko's Avatar
published in Blogs
Jun 19, 2025

Analysis of Tilray Brands' (TLRY) Stock for June 2025: Market Trends and AI-Powered Perspectives

Tilray Brands, Inc. (Nasdaq: TLRY) is a global leader in the cannabis, beverage, and wellness industries, headquartered in New York and Leamington, Ontario. As a prominent player in the cannabis sector, Tilray has garnered significant investor attention due to its strategic expansions and market performance. This article provides a comprehensive financial analysis of TLRY as of June 19, 2025, incorporating recent market movements, statistical data, comparisons with correlated stocks and inverse ETFs, and the role of AI-driven tools like those offered by Tickeron.com. The analysis also explores how traders can leverage these tools to navigate TLRY’s volatility and optimize their strategies.

TLRY Stock Performance: Recent Trends and Statistics

Tilray Brands has experienced notable volatility in 2025, reflective of the broader cannabis industry and macroeconomic factors. As of June 11, 2025, TLRY closed at $0.42, marking a +2.37% increase from the prior trading day, according to Yahoo Finance. Over the past week, the stock saw a 4.82% price increase, coinciding with the company’s approval of a reverse stock split, which grants greater flexibility in its stock structure. This performance aligns with a positive market environment, as the S&P 500 and Nasdaq recorded gains amid favorable inflation data and U.S.-China trade developments.

Key Financial Metrics

  • Market Capitalization: As of June 2025, Tilray’s market cap stands at approximately $320 million, reflecting its position as a mid-cap stock in the cannabis sector.
  • Price-to-Sales Ratio: TLRY’s price-to-sales ratio is around 0.4x, indicating a potentially undervalued stock relative to its revenue generation.
  • Debt Reduction: In the fiscal quarter ending February 28, 2025, Tilray reduced its total debt by $76 million, achieving a net debt to trailing twelve-month Adjusted EBITDA ratio of less than 1.0x, signaling improved financial health.
  • Trading Volume: Over the five trading days ending June 10, 2025, TLRY’s average daily trading volume was approximately 1.2 million shares, indicating moderate liquidity for a stock in its sector.
  • Year-to-Date Performance: TLRY has faced challenges in 2025, with its stock price down approximately 65% from its January high of $1.20, as noted in posts on X.

Technical Indicators

TLRY’s MACD Histogram crosses above the signal line

The Moving Average Convergence Divergence (MACD) for TLRY turned positive on June 10, 2025. Looking at past instances where TLRY’s MACD turned positive, the stock continued to rise in 38 of 43 cases over the following month. The odds of a continued upward trend are 88%.

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 54 of 62 cases where TLRY’s Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron’s analysis proposes that the odds of a continued upward trend are 87%.

Following a +3.85% 3-day Advance, the price is estimated to grow further. Considering data from situations where TLRY advanced for three days, in 161 of 198 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.

TLRY may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on June 17, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on TLRY as a result. In 68 of 80 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 85%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where TLRY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

The Aroon Indicator for TLRY entered a downward trend on June 06, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Market News Impacting TLRY: June 19, 2025

The stock market on June 19, 2025, reflects a complex interplay of macroeconomic and geopolitical factors influencing TLRY’s performance. Key market news includes:

  • Geopolitical Tensions: Stocks experienced volatility earlier in the week due to escalating conflicts between Israel and Iran, which pushed energy prices higher and led to a market downturn on June 13. The S&P 500 fell 1.13% to 5,976.97, and the Nasdaq Composite dropped 1.30% to 19,406.83. This broader market decline likely pressured TLRY, given its sensitivity to market sentiment.
  • Federal Reserve Policy: Investors are closely monitoring the Federal Reserve’s two-day meeting, which began on June 17, for indications of interest rate decisions. Expectations of steady rates in 2025, despite cooling inflation, suggest a cautious market environment that could impact high-beta stocks like TLRY.
  • Sector-Specific Developments: The cannabis sector remains under scrutiny due to regulatory uncertainties. However, Tilray’s recent debt reduction and strategic focus on beverage and wellness products position it favorably for long-term growth, even amidst short-term market fluctuations.

Comparison with a Correlated Stock: Canopy Growth Corporation (CGC)

Tilray’s stock performance is closely correlated with other cannabis industry players, notably Canopy Growth Corporation (Nasdaq: CGC). Both companies operate in the global cannabis market and are influenced by similar regulatory and market dynamics. Over the past year, TLRY and CGC have shown a correlation coefficient of approximately 0.85, indicating strong alignment in price movements.

  • Recent Performance: As of June 2025, CGC has also faced significant declines, trading at around $0.65, down 70% year-to-date, mirroring TLRY’s challenges. However, CGC’s larger market cap ($600 million) and broader international presence give it a slightly different risk profile.
  • Key Differences: While Tilray has diversified into beverages and wellness, CGC focuses heavily on cannabis-based pharmaceuticals. This divergence could lead to varied responses to regulatory changes, such as potential U.S. federal legalization, which some X users speculate could drive TLRY to $1.20 or higher.
  • Trading Insights: Investors tracking TLRY and CGC can leverage Tickeron’s AI-driven analytics to compare real-time trends, identifying which stock may offer better upside based on technical indicators like moving average crossovers or relative strength index (RSI).

Leveraging Inverse ETFs for Trading TLRY

For traders seeking to hedge TLRY’s volatility, inverse ETFs like the ProShares Short S&P 500 (SH) offer an anti-correlated instrument. SH aims to deliver the daily inverse performance of the S&P 500, which indirectly anti-correlates with TLRY due to its inclusion in broader market indices. During TLRY’s 4.82% weekly gain in early June 2025, SH likely declined by a similar magnitude, reflecting its inverse relationship.

  • Strategic Advantage: Pairing TLRY with SH allows traders to mitigate losses during market downturns. For instance, if TLRY declines due to sector-specific headwinds, SH’s gains can offset losses, providing a balanced portfolio approach.
  • Risk Considerations: Inverse ETFs like SH are designed for short-term strategies due to daily rebalancing, which can lead to compounding losses in prolonged trends. Tickeron’s AI tools can help traders identify optimal entry and exit points for SH, ensuring precise hedging in TLRY’s volatile trajectory.

Tickeron’s AI Trading Agents: Enhancing TLRY Strategies

Tickeron, led by CEO Sergey Savastiouk, has transformed trading through its Financial Learning Models (FLMs), which integrate machine learning with technical analysis to deliver high-probability trade setups. For TLRY, Tickeron’s AI Trading Robots and Double Agents provide dual-perspective signals, capturing both bullish and bearish trends. For example, Tickeron’s platform identified a bullish moving average crossover for TLRY on May 15, 2025, signaling potential upside to $0.50. By pairing TLRY with inverse ETFs like SH, Tickeron’s Double Agents offer a hedged approach, achieving a +9.77% quarterly gain in a declining market. These tools, accessible at Tickeron’s bot-trading platform, empower traders to navigate TLRY’s volatility with precision, making them essential for both novice and experienced investors.

Conclusion

Tilray Brands (TLRY) remains a compelling yet volatile investment in the cannabis sector as of June 19, 2025. Its recent 4.82% weekly gain, debt reduction, and strategic approval of a reverse stock split signal potential for recovery, despite a challenging year-to-date performance. By comparing TLRY with correlated stocks like CGC and leveraging inverse ETFs like SH, investors can balance risk and reward. Tickeron’s AI-driven tools, with their advanced Financial Learning Models, provide real-time insights and hedging strategies, making them invaluable for navigating TLRY’s market movements. As macroeconomic and regulatory developments unfold, traders should remain vigilant, using platforms like Tickeron.com to stay ahead in this dynamic sector.

Disclaimers and Limitations

Related Ticker: TLRY, CGC

Contributor

Serhii Bondarenko is an AI-focused trading strategist and financial markets analyst specializing in the development and application of AI trading bots and autonomous trading agents. His work combines technical analysis, fundamental analysis, and quantitative research to identify market patterns, forecast price movements, and analyze liquidity, volatility, and correlations across global stock markets. Serhii actively publishes market insights, forecasts, and trading frameworks on platforms such as Investing.com and Finextra, with a strong focus on AI-driven decision-making and next-generation algorithmic trading. His research aims to bridge the gap between traditional trading methodologies and advanced artificial intelligence, helping traders and investors navigate complex and rapidly evolving market conditions.


TLRY's Stochastic Oscillator drives into overbought zone

The Stochastic Oscillator for TLRY moved into overbought territory on August 21, 2026. Be on the watch for a price drop or consolidation in the future -- when this happens, think about selling the stock or exploring put options.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where TLRY declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

TLRY broke above its upper Bollinger Band on August 03, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for TLRY entered a downward trend on July 31, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where TLRY's RSI Indicator exited the oversold zone, of 46 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on August 19, 2026. You may want to consider a long position or call options on TLRY as a result. In of 77 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for TLRY just turned positive on July 30, 2026. Looking at past instances where TLRY's MACD turned positive, the stock continued to rise in of 39 cases over the following month. The odds of a continued upward trend are .

TLRY moved above its 50-day moving average on August 19, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for TLRY crossed bullishly above the 50-day moving average on August 13, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where TLRY advanced for three days, in of 204 cases, the price rose further within the following month. The odds of a continued upward trend are .

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.412) is normal, around the industry mean (40.756). P/E Ratio (0.000) is within average values for comparable stocks, (94.098). TLRY's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.238). TLRY has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.030). P/S Ratio (0.591) is also within normal values, averaging (177.108).

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. TLRY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TLRY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.

Notable companies

The most notable companies in this group are Teva Pharmaceutical Industries Limited (NYSE:TEVA), ZOETIS (NYSE:ZTS), Elanco Animal Health (NYSE:ELAN), BioCryst Pharmaceuticals (NASDAQ:BCRX), Bausch Health Companies (NYSE:BHC), Tilray Brands Inc. (NASDAQ:TLRY), Canopy Growth Corp (NASDAQ:CGC), Aurora Cannabis (NASDAQ:ACB), Journey Medical Corp (NASDAQ:DERM).

Industry description

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

Market Cap

The average market capitalization across the Pharmaceuticals: Generic Industry is 4.12B. The market cap for tickers in the group ranges from 2.12K to 63.66B. AGN holds the highest valuation in this group at 63.66B. The lowest valued company is CANQF at 2.12K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Generic Industry was 2%. For the same Industry, the average monthly price growth was 7%, and the average quarterly price growth was 31%. AMLX experienced the highest price growth at 79%, while AKAN experienced the biggest fall at -40%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Generic Industry was 11%. For the same stocks of the Industry, the average monthly volume growth was -10% and the average quarterly volume growth was -28%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 52
P/E Growth Rating: 65
Price Growth Rating: 56
SMR Rating: 88
Profit Risk Rating: 82
Seasonality Score: -9 (-100 ... +100)
View a ticker or compare two or three
TLRY
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

a holding company, whose subsidiaries engages in research, cultivation, processing and distribution of medical cannabis

Industry PharmaceuticalsGeneric

Profile
Details
Industry
Biotechnology
Address
265 Talbot Street West
Phone
+1 844 845-7291
Employees
1600
Web
https://www.tilray.com
Interact to see
Advertisement
ERII shares have remained resilient, trading near $15.47 ahead of Q4 and full-year 2025 earnings scheduled for February 25, 2026. Q3 2025 results exceeded expectations, with revenue of $32 million and EPS of $0.07, despite year-over-year declines tied to project timing.
Liberty Broadband Corporation (LBRDA) has experienced pronounced swings in recent weeks, touching multiyear lows before staging a sharp recovery. The stock continues to trade within a wide 52-week range, closely tied to the value of its Charter Communications stake and investor expectations around the proposed merger.
Arm Holdings (ARM) shares have demonstrated resilience in recent sessions, rebounding after an initial earnings-related pullback and stabilizing near technical support levels. While smartphone-related headwinds tied to memory shortages pressured sentiment, momentum in AI-driven data center royalties helped restore confidence.
Shell plc (SHEL) reported Q4 2025 adjusted earnings of $3.3 billion, below expectations due to weaker oil prices and non-cash tax charges. Full-year adjusted earnings reached $18.5 billion, supported by strong LNG and upstream operations. A 4% dividend increase to $0.372 per share and a new $3.5 billion buyback program reinforce capital return commitments.
Linde (LIN) reported Q4 2025 adjusted EPS of $4.20, topping estimates, with full-year revenue reaching $34 billion. 2026 EPS guidance of $17.40–$17.90 implies 6–9% growth, supported by a record $10 billion project backlog.
ConocoPhillips (COP) reported Q4 2025 adjusted EPS of $1.02, missing estimates due to weaker oil prices. Full-year adjusted earnings totaled $7.7 billion, with $19.9 billion in operating cash flow. Shares have gained more than 10% in recent weeks, supported by analyst upgrades and sector momentum.
Verisk Analytics (VRSK) delivered Q4 2025 revenue of $779 million, up 5.9% year over year, with adjusted EPS of $1.82, beating expectations. Booz Allen Hamilton (BAH) reported Q3 FY2026 revenue of $2.62 billion, down 10.2% year over year, but adjusted diluted EPS climbed 14% to $1.77, well above estimates.
(OMC) Omnicom’s fourth-quarter report, released February 18, 2026, marked its first earnings update incorporating results from Interpublic Group (IPG), acquired on November 26, 2025. The combination created the world’s largest marketing services firm by revenue, a significant milestone as the advertising industry consolidates and adapts to digital transformation.
Copart (CPRT) is set to report fiscal Q2 2026 earnings on February 19, 2026, after market close. Consensus calls for EPS of $0.39–$0.40 and revenue of $1.15–$1.18 billion. Global Payments (GPN) posted Q4 2025 adjusted EPS of $3.18, in line with expectations, and adjusted net revenue of $2.32 billion, up 6% in constant currency (excluding dispositions). Thomson Reuters (TRI) delivered Q4 2025 adjusted EPS of $1.07 and revenue of $2.01 billion, up 5% year over year, supported by recurring subscription growth.
Unilever PLC (UL) leads year-to-date performance with a 12.61% gain, ahead of Diageo plc (DEO) at 9.90% and Keurig Dr Pepper Inc. (KDP) at 4.27%. DEO offers the highest dividend yield at 4.35%, compared with KDP (3.16%) and UL (2.97%). All three stocks carry low betas—DEO (0.18), UL (0.24), and KDP (0.35)—highlighting their defensive characteristics.
Q1 Fiscal 2026 Results: Revenue of $333M and adjusted EBITDA of $50M (15% margin), exceeding analyst expectations. FY2026 Guidance Raised: Adjusted EBITDA now projected at $225M, with revenue reaffirmed near $1.5B. EV Backlog Growth: 855 electric buses worth $277M, highlighting robust demand supported by EPA clean bus funding.
IBM fell over 10% today mainly because a new AI tool from Anthropic is seen as a direct threat to IBM’s lucrative COBOL modernization and consulting business, triggering worries that key legacy‑modernization revenue will be automated away.
Today’s drop is mainly about competitive positioning and future growth expectations, not an immediate collapse of current Wegovy/Ozempic sales, but it signals that Novo may not have the strongest next‑wave obesity drug versus Eli Lilly, which is why the stock sold off so sharply.
RNG (RingCentral) dropped over 12% today mainly as a sharp pullback after a very steep recent run‑up driven by upbeat Q4 results, guidance, and capital‑return news, with profit‑taking amplified by valuation concerns and a weak broader tech tap
Fundamentally, the latest public guidance is still for rapid growth and profitability, but today’s drop reflects a reset of sentiment and valuation rather than a brand‑new deterioration in those targets. For investors, the key question is whether the current price appropriately reflects execution risk, competition in diagnostics, and macro volatility after the guidance‑driven rally and subsequent reversal.
TNC (Tennant Company) is down more than 25% today because it reported a very large earnings and revenue miss for Q4 2025, blamed on serious ERP rollout problems and weaker demand, and guided to a slower‑than‑hoped recovery in 2026.
XMTR (Xometry) is down more than 21% today because, despite reporting record growth and an earnings beat, the company announced a CEO transition and investors used the news to take profits after a big prior run‑up, with heavy short interest amplifying the drop.
EDSA (Edesa Biotech) is up more than 21% today largely on speculative trading in a very illiquid penny stock with no clear, company‑specific news catalyst, likely driven by technical factors, retail flows, and short‑term trading rather than fundamentals.
Q4 2025 revenue came in strong at about 214–215 million, up mid‑30s percent year over year and a few percent above estimates, but GAAP EPS was only 0.08 versus expectations around 0.31, a roughly 70–75% miss and down from 0.13 a year earlier.
Estée Lauder Companies Inc. (EL) has rebounded with ~12% YTD gains and 50%+ one-year returns, supported by margin improvements and strong skincare/fragrance demand despite broader prestige beauty challenges.